Molecule News and Research

RSS

Researchers show iRGD peptide increases treatment efficacy against cancer

Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.

9 Apr 2010

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.

9 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

Researchers document the beneficial health effects of omega-3 fatty acids

The health benefits of omega-3 fatty acids are widely proven. But how can these nutrients be absorbed most effectively into the body? And do they have any potentially negative effects? Norwegian researchers are seeking answers to these questions.

8 Apr 2010

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Synta will present multiple posters at the American Association for Cancer Research 101st Annual Meeting 2010 to be held April 17-21, 2010 in Washington, DC.

8 Apr 2010

OSU-CG12 agent kills cancer cells through energy restriction: Study

Cancer cells grow so fast that they can outstrip their blood supply, leaving them short of oxygen. The cells then produce energy in a way that needs less oxygen but more sugar.

8 Apr 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is expressed on malignant Hodgkin lymphoma cells.

8 Apr 2010

Scientists discover how mechanical stress promotes new bone growth

For osteoporosis patients unable to exercise, help may be on the way. That's because scientists have discovered precisely how mechanical stress, such as exercise, promotes new bone growth. This opens the door to entirely new therapies that can trick bones into thinking they are getting a workout. The research report describing this advance is published online in The FASEB Journal.

8 Apr 2010

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

7 Apr 2010

Achaogen announces completion of $56M Series C round of financing

Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, today announced the completion of a $56 million Series C round of financing. The round was led by new investor Frazier Healthcare Ventures, and also included new investor Alta Partners.

7 Apr 2010

Complex organic molecules speed development of new drugs

Professor Varinder Aggarwal is no ordinary builder. He and his team in the School of Chemistry have just discovered a new technique that could hasten the development of new drugs for today’s incurable diseases – by building complex organic molecules.

7 Apr 2010

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com announces an investment report featuring Repros Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Messenger substance plays significant role in viral diseases and reactions to infections

The connection with the blood circulatory system is a significant step in the development of cancer. Within the tissue where it is growing, the tumour develops an independent existence. With signal substances it entices white blood cells from the bone marrow into the tumour tissue.

6 Apr 2010

Cephalon acquires biotechnology company, Ception Therapeutics

Cephalon, Inc. announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc. and that Ception is now a wholly-owned subsidiary of Cephalon.

6 Apr 2010

Kyto Biopharma enters agreement with Targeted Payload Therapeutics

Kyto Biopharma Inc., is a Florida biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

3 Apr 2010

New production method yields hundredsfold more ubiquitylated proteins critical for cancer research

Scientists at the University of Delaware have developed a new method for producing proteins critical to research on cancer, Alzheimer's, and other diseases.

3 Apr 2010

Brain stem cells in subventricular zone characterized by transcription factor Protein Tlx

The "cradle" of new neurons in the adult brain is well known. It is what is called the subventricular zone, a tissue structure lining the lateral ventricles. This is where neural or brain stem cells reside, which are responsible for generating new neurons if needed. For many years now, the subventricular zone has been suspected to be the origin of specific malignant brain tumors called gliomas, the most deadly type of which is glioblastoma.

2 Apr 2010

Protein vaccines for needle-free immunization through the skin

Most immunizations currently involve an injection in the arm. In the future, vaccination may be accomplished without the unpleasant jab of a needle: a team led by Victor C. Yang at the University of Michigan (USA) has developed a method by which vaccines can pass directly through the skin without a needle. As the researchers report in the journal Angewandte Chemie, merely linking a special short peptide molecule to the vaccine, which can then be administered in the form of a patch, will do the job.

1 Apr 2010

BeaconEquity.com announces investment report featuring OXiGENE

BeaconEquity.com announces an investment report featuring OXiGENE Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

1 Apr 2010

Molecule News and Research

Researchers show iRGD peptide increases treatment efficacy against cancer

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

Researchers document the beneficial health effects of omega-3 fatty acids

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

OSU-CG12 agent kills cancer cells through energy restriction: Study

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Scientists discover how mechanical stress promotes new bone growth

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Achaogen announces completion of $56M Series C round of financing

Complex organic molecules speed development of new drugs

StockPreacher.com releases investment report on Repros Therapeutics

Messenger substance plays significant role in viral diseases and reactions to infections

Cephalon acquires biotechnology company, Ception Therapeutics

Kyto Biopharma enters agreement with Targeted Payload Therapeutics

New production method yields hundredsfold more ubiquitylated proteins critical for cancer research

Brain stem cells in subventricular zone characterized by transcription factor Protein Tlx

Protein vaccines for needle-free immunization through the skin

BeaconEquity.com announces investment report featuring OXiGENE

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News